1
Lymphomas
August 2015
This bulletin covers aspects of lymphomas and should be of interest to multidisciplinary teams working in
this area.
Sections can include:
 Combined Modality Therapies
 Drug & Biological Therapies
 Pathology, Staging, Polymorphisms & Biomarkers
 Prognosis, Survival & Risk Factors
 Radiotherapy & Imaging
 Stem Cell Transplantation
 Supportive Care & Symptom Management
Many of the following articles are available online via the NHS Scotland Knowledge Network.
Please use the links where provided and your ATHENS password. A complete list of available
online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you would
like to request a print copy, please submit your request online at www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is not
intended to be comprehensive. Professional judgment should be exercised when appraising the material.
The Library takes no responsibility for the wording, content and accuracy of the information supplied,
which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the
content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk
1
2
General
Hapgood G and Savage KJ. (2015). The biology and management of systemic anaplastic large cell
lymphoma. Blood 126,1:17-25.
Hoang-Xuan K, Bessell E, Bromberg J, et al. (2015). Diagnosis and treatment of primary CNS
lymphoma in immunocompetent patients: guidelines from the European Association for NeuroOncology. Lancet Oncology 16,7:e322-32.
Vose, J.M. (2015). Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical
management. American Journal of Hematology 90,8:739-745.
Combined Modality Therapies
Bi XW, Jiang WQ, Zhang WW, et al. (2015). Treatment outcome of patients with advanced stage
natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic
radiotherapy. Annals of Hematology 94,7:1175-1184.
Bonthapally V, Yang H, Ayyagari R, et al. (2015). Brentuximab vedotin compared with other therapies
in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall
survival meta-analysis. Current Medical Research & Opinion 31,7:1377-1389.
Hu C, Deng C, Zou W, et al. (2015). The Role of Consolidative Radiotherapy after a Complete
Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab
Era: Results from a Systematic Review with a Meta-Analysis. Acta Haematologica 134,2:111-118.
Narang AK and Terezakis SA. (2015). Contemporary radiation therapy in combined modality therapy
for Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network 13,5:597-605.
Perales MA, Ceberio I, Armand P, et al. (2015). Role of cytotoxic therapy with hematopoietic cell
transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for
Blood and Marrow Transplantation. Biology of Blood & Marrow Transplantation 21,6:971-983.
Sun H, Savage KJ, Karsan A, et al. (2015). Outcome of Patients With Non-Hodgkin Lymphomas With
Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab
Followed by Hematopoietic Stem Cell Transplantation. Clinical lymphoma, myeloma & leukemia
15,6:341-348.
Drug & Biological Therapies
Belada D, Stepankova P, Sykorova A, et al. (2015). Ten years' experience with four cycles of
bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine
(BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with
advanced stage Hodgkin lymphoma: a single-center, retrospective study. Leukemia & lymphoma
56,7:2013-2018.
2
3
Bozzoli V, Tisi MC, Maiolo E, et al. (2015). Four doses of unpegylated versus one dose of pegylated
filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell
lymphoma. British journal of haematology 169,6:787-794.
Ghose A, Elias HK, Guha G, et al. (2015). Influence of Rituximab on Central Nervous System
Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis-A Systematic Review of
Prospective Studies. Clinical lymphoma, myeloma & leukemia 15,8:451-457.
Samaniego F, Hagemeister F, Romaguera JE, et al. (2015). Pentostatin, cyclophosphamide and
rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. British journal of
haematology 169,6:814-823.
Tucker DL and Rule SA. (2015). A critical appraisal of ibrutinib in the treatment of mantle cell
lymphoma and chronic lymphocytic leukemia. Therapeutics & Clinical Risk Management 11,979-990.
Wang Y, Zhang LL, Champlin RE, et al. (2015). Targeting Bruton's tyrosine kinase with ibrutinib in Bcell malignancies. Clinical Pharmacology & Therapeutics 97,5:455-468.
Witzig TE, Nowakowski GS, Habermann TM, et al. (2015). A comprehensive review of lenalidomide
therapy for B-cell non-Hodgkin lymphoma. Annals of Oncology 26,8:1667-1677.
Pathology, Staging, Polymorphisms & Biomarkers
Eyre TA and Collins GP. (2015). Immune checkpoint inhibition in lymphoid disease. British journal of
haematology 170,3:291-304.
Hawkes EA, Grigg A and Chong G. (2015). Programmed cell death-1 inhibition in lymphoma. Lancet
Oncology 16,5:e234-45.
Sahasrabuddhe AA and Elenitoba-Johnson KS. (2015). The role of aberrant proteolysis in
lymphomagenesis. Current opinion in hematology 22,4:369-378.
Testoni M, Zucca E, Young KH, et al. (2015). Genetic lesions in diffuse large B-cell lymphomas.
Annals of Oncology 26,6:1069-1080.
Prognosis, Survival & Risk Factors
Chen YP, Huang HY, Lin KP, et al. (2015). Malignant effusions correlate with poorer prognosis in
patients with diffuse large B-cell lymphoma. American Journal of Clinical Pathology 143,5:707-715.
Kreher S, Johrens K, Strehlow F, et al. (2015). Prognostic impact of B-cell lymphoma 6 in primary
CNS lymphoma. Neuro-oncology 17,7:1016-1021.
Mank AP, Schoonenberg C, Bleeker K, et al. (2015). Early discharge after high dose chemotherapy is
safe and feasible: a prospective evaluation of 6 years of home care. Leukemia & lymphoma
56,7:2098-2104.
3
4
Panizo C, Rodriguez AJ, Gutierrez G, et al. (2015). Evaluation of Clinical and Biological Prognostic
Factors in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients After Previous
Treatment With Rituximab and Chemotherapy: Results of the PRO-R-IPI Study. Clinical lymphoma,
myeloma & leukemia 15,7:398-403.
Rupani A, Frame JD and Kamel D. (2015). Lymphomas Associated with Breast Implants: A Review
of the Literature. Aesthetic Surgery Journal 35,5:533-544.
Radiotherapy & Imaging
Adams HJ, Nievelstein RA and Kwee TC. (2015). Prognostic value of complete remission status at
end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review
and meta-analysis. British journal of haematology 170,2:185-191.
Adams HJ, Nievelstein RA and Kwee TC. (2015). Prognostic value of interim FDG-PET in Hodgkin
lymphoma: systematic review and meta-analysis. British journal of haematology 170,3:356-366.
Advani RH, Hong F, Fisher RI, et al. (2015). Randomized Phase III Trial Comparing ABVD Plus
Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky
Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
Journal of Clinical Oncology 33,17:1936-1942.
Johnson SA, Kumar A, Matasar MJ, et al. (2015). Imaging for Staging and Response Assessment in
Lymphoma. Radiology 276,2:323-338.
Milgrom SA and Yahalom J. (2015). The role of radiation therapy in the management of primary
central nervous system lymphoma. Leukemia & lymphoma 56,5:1197-1204.
Miltenyi Z, Barna S, Garai I, et al. (2015). Prognostic value of interim and restaging PET/CT in
Hodgkin lymphoma. Results of the CHEAP (Chemotherapy Effectiveness Assessment by PET/CT)
study - long term observation. Neoplasma 62,4:627-634.
Murray L, Sethugavalar B, Robertshaw H, et al. (2015). Involved Node, Site, Field and Residual
Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second
Malignancy Risks. Clinical Oncology (Royal College of Radiologists) 27,7:401-410.
Simontacchi G, Filippi AR, Ciammella P, et al. (2015). Interim PET After Two ABVD Cycles in EarlyStage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus
Radiotherapy. International journal of radiation oncology, biology, physics 92,5:1077-1083.
Specht L, Dabaja B, Illidge T, et al. (2015). Modern radiation therapy for primary cutaneous
lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology
Group. International journal of radiation oncology, biology, physics 92,1:32-39.
Yahalom J, Illidge T, Specht L, et al. (2015). Modern radiation therapy for extranodal lymphomas:
field and dose guidelines from the International Lymphoma Radiation Oncology Group.
International journal of radiation oncology, biology, physics 92,1:11-31.
4
5
Special Populations
Jourdain A, Auperin A, Minard-Colin V, et al. (2015). Outcome of and prognostic factors for relapse in
children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive
prospective "Lymphomes Malins B" protocols. A Societe Francaise des Cancers de l'Enfant
study. Haematologica 100,6:810-817.
Mauz-Korholz C, Hasenclever D, Holzendorf V, et al. (2015). Feasibility of VECOPA, a dose-intensive
chemotherapy regimen for children and adolescents with intermediate and advanced stage
Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial. Leukemia & lymphoma
56,5:1308-1314.
Jung SH, Lee JJ, Kim WS, et al. (2015). Weekly rituximab consolidation following four cycles of RCHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma:
Consortium for improving survival of lymphoma study (CISL). European journal of haematology
94,6:504-510.
Supportive Care & Symptom Management
Meissner J, Tichy D, Katzke V, et al. (2015). Long-term ovarian function in women treated with CHOP
or CHOP plus etoposide for aggressive lymphoma. Annals of Oncology 26,8:1771-1776.
Peng L, Ye X, Zhou Y, et al. (2015). Meta-analysis of incidence and risk of peripheral neuropathy
associated with intravenous bortezomib. Supportive Care in Cancer 23,9:2813-2824.
Taylor K, Chan RJ and Monterosso L. (2015). Models of survivorship care provision in adult patients
with haematological cancer: an integrative literature review. Supportive Care in Cancer 23,5:14471458.
Transplantation
Bojic M, Berghoff AS, Troch M, et al. (2015). Haematopoietic stem cell transplantation for treatment
of primary CNS lymphoma: single-centre experience and literature review. European journal of
haematology 95,1:75-82.
Cheminant M, Robinson S, Ribrag V, et al. (2015). Prognosis and outcome of stem cell
transplantation for mantle cell lymphoma. Expert Review of Hematology 8,4:493-504.
Farooq U and Laport GG. (2015). Recent progress: hematopoietic cell transplant for diffuse large Bcell lymphoma. Leukemia & lymphoma 56,7:1930-1937.
5
6
Please note that the journal articles you are accessing are subject to the terms and conditions imposed
by the publisher, so there will be a limit on the number of articles an individual may download or print from
a single issue of a journal. You can consult your local NHSGGC library with any queries.
If you have any questions regarding this or any other library services please contact Library staff –
contact details are at the beginning of the bulletin.
Sources used for this bulletin:
OVID MEDLINE, SIGN, NICE and Healthcare Improvement Scotland
6